Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established ri
The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug with the added benefit of glucose reduct
Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market.
Two diabetes drugs, Lilly and Boehringer Ingelheim’s (BI) Jardiance and Novo Nordisk’s Victoza, have shown they can go beyond lowering blood sugar, and actually save lives and cut heart attacks
